Amantadine Treatment and Delayed Onset of Levodopa‐Induced Dyskinesia in Patients with Early Parkinson’s Disease

2021 ◽  
Author(s):  
Chi‐Chuan Wang ◽  
Tsai‐Ling Wu ◽  
Fang‐Ju Lin ◽  
Chun‐Hwei Tai ◽  
Chin‐Hsien Lin ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Delayed Onset ◽  
Early Parkinson’S Disease

1.128 Are there multisensory defcits in early Parkinson's disease? A case-control study

2007 ◽  
Vol 13 ◽  
pp. S40-S41
Author(s):  
V. Pieri ◽  
M. Vaillant ◽  
S. Blyth ◽  
G. Hipp ◽  
N.J. Diederich
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Case Control Study ◽  
Case Control ◽  
Early Parkinson’S Disease ◽  
Control Study

scholarly journals Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease

2021 ◽  
Author(s):  
Thomas Kremer ◽  
Kirsten I. Taylor ◽  
Juliane Siebourg‐Polster ◽  
Thomas Gerken ◽  
Andreas Staempfli ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Longitudinal Analysis ◽  
Early Parkinson’S Disease ◽  
Neurotransmitter Metabolites

Nose swab could point to early Parkinson's disease

2021 ◽  
Vol 250 (3335) ◽  
pp. 14
Author(s):  
Clare Wilson
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Early Parkinson’S Disease

Medical follow up assessments of iPrognosis application users for early Parkinson's disease detection

2020 ◽  
Vol 79 ◽  
pp. e37
Author(s):  
L. Klingelhoefer ◽  
S. Bostanjopoulou ◽  
D. Trivedi ◽  
S. Hadjidimitriou ◽  
D. Hausbrand ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Detection ◽  
Early Parkinson’S Disease

Value of combined midbrain sonography, olfactory and motor function assessment in the differential diagnosis of early Parkinson's disease

2012 ◽  
Vol 83 (4) ◽  
pp. 441-447 ◽  
Author(s):  
Knut Busse ◽  
Robert Heilmann ◽  
Sabine Kleinschmidt ◽  
Mazen Abu-Mugheisib ◽  
Jacqueline Höppner ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Differential Diagnosis ◽  
Motor Function ◽  
Early Parkinson’S Disease ◽  
Function Assessment

scholarly journals Treatment of Early Parkinson's Disease

1999 ◽  
Vol 26 (S2) ◽  
pp. S39-S44 ◽  
Author(s):  
David A. Grimes ◽  
Anthony E. Lang
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Early Treatment ◽  
Dopaminergic Neurons ◽  
Symptomatic Therapy ◽  
Potential Toxicity ◽  
Significant Disability ◽  
Early Parkinson’S Disease

The early treatment of Parkinson's disease continues to be controversial as our understanding of the etiology of the disease remains incomplete. Ideally an intervention that reverses or protects against further damage to dopaminergic neurons would be initiated once the symptoms of the disease are recognized. Unfortunately, there are no currently available therapies that have been shown to have a major impact on the progression of the disease. However, delaying effective symptomatic therapy beyond a point of significant disability does result in increased mortality. Concerns have been raised regarding the potential toxicity of levodopa on remaining nigral neurons. Although there is little support for this concept, levodopa is associated with important complications. The development of new symptomatic treatments has made the management of early Parkinson's disease even more complex and requires that many different factors be considered prior to initiating therapy in an attempt to minimize current and future disability caused by the disease and its treatment.

Sign in / Sign up

Export Citation Format

Share Document